Please login to the form below

Not currently logged in
Email:
Password:

pain

This page shows the latest pain news and features for those working in and with pharma, biotech and healthcare.

Brexit contributes to surge in generic drug prices

Brexit contributes to surge in generic drug prices

He says some medicines would be “particularly vulnerable" - highlighting a current shortage of pain and opioid addiction treatment Buprenorphine and antipsychotic Risperidone, arising in particular because there are no simple alternatives

Latest news

  • Lilly partners with AC Immune on tau drug for Alzheimer’s Lilly partners with AC Immune on tau drug for Alzheimer’s

    Mark Mintun. Lilly is undeterred by those setbacks however, and Mark Mintun – the company’s vice president of neurodegeneration and pain research – said that the agreement with AC Immune “represents another

  • FDA clears Sandoz and Pear’s Opioid Use Disorder app FDA clears Sandoz and Pear’s Opioid Use Disorder app

    Corey McCann, President and CEO of Pear Therapeutics, said: “Nearly 50, 000 drug overdose deaths involving opioids, including prescription pain medications and heroin, took place in the US in 2017.

  • AbbVie preps uterine fibroid filing after phase 3 win AbbVie preps uterine fibroid filing after phase 3 win

    the drug in endometriosis pain. ... In many cases they cause no symptoms, but around a quarter of women experience pain, abnormal bleeding and other symptoms, and may experience fertility problems.

  • The Final Frontier The Final Frontier

    They sent questionnaires to households asking about self-reported pain frequency, intensity and persistency. ... Depending on how you interpret the results, anywhere from 19-44% of Canadians self-report as being afflicted with chronic pain.

  • Medical cannabis now available on prescription, for some Medical cannabis now available on prescription, for some

    The list doesn’t include chronic pain, however, which is thought to be one of the main drivers for medicinal use of cannabis. ... for instance in the areas of cancer pain and chemotherapy induced nausea and vomiting,” she adds.

More from news
Approximately 15 fully matching, plus 733 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.

  • Nudge-nudge, think-think Nudge-nudge, think-think

    Children with JIA find it difficult to verbalise their symptoms and therefore often do not communicate their pain. ... We created a simple wristband; one side was white (signalling they were fine) and one side was red (signalling they were in pain).

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    One potential major product launch for 2019 will be novel pain drug tanezumab. ... These new products will help offset the patent expiry of one of Pfizer’s biggest products, pain treatment Lyrica, which will see generics arrive at the end of December.

  • In conversation with Pfizer’s Erik Nordkamp In conversation with Pfizer’s Erik Nordkamp

    restrictive. During the most difficult times, politicians had to choose where they took the pain within a severely constrained budget, but they always prioritised healthcare and access to the most innovative

  • Insights from Cannes Lions Health Festival 2018 Insights from Cannes Lions Health Festival 2018

    sea. He describes the impact – the pain, the chaos and the suffering – and we experience the attack with him through Jaws-style shots.

More from intelligence
Approximately 0 fully matching, plus 83 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 23 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 59 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics